INDUSTRY WORKSHOP: Shaping the Future of Drug Testing & Diagnostics: Automation Meets Mass Spectrometry
Tracks
Track 1
| Monday, September 22, 2025 |
| 12:30 PM - 1:25 PM |
| Grand Copthorne Waterfront Hotel - Grand Ballroom I |
| Sponsored By: |
Overview
Delivered by: Roche Diagnostics
Details
Disclaimer:
cobas Ⓡ i 601 analyzer and Ionify Steroids 1 and Vitamin D reagent packs are CE-marked. Further Ionify reagents are still under development. These products are not cleared or available for use in the US. COBAS and IONIFY are trademarks of Roche. This study was funded by Roche Diagnostics
GmbH, Mannheim.
Research funding: This research was funded by Roche Diagnostics GmbH.
Speaker
YaYuan Lin
International Product Manager Mass Spectrometry
Roche Diagnostics International
Shaping the Future of Therapeutic Drug Monitoring & Drugs of Abuse Testing
Abstract
At this year’s IATDMCT congress, Roche will showcase its integrated approach to Therapeutic Drug Monitoring (TDM) and drug testing, combining mass spectrometry, Immunochemistry and
Clinical Chemistry methods to deliver complementary, efficient, and scalable solutions.
This session will highlight cutting-edge workflow optimization and advancements that enhance testing efficiency, standardization, and clinical decision-making. By integrating innovative technologies, Roche expands testing capabilities and precision diagnostics, reinforcing its commitment to innovation and leadership in drug testing and monitoring. Through continuous advancements in laboratory medicine, Roche is shaping the future of drug testing and diagnostics.
Clinical Chemistry methods to deliver complementary, efficient, and scalable solutions.
This session will highlight cutting-edge workflow optimization and advancements that enhance testing efficiency, standardization, and clinical decision-making. By integrating innovative technologies, Roche expands testing capabilities and precision diagnostics, reinforcing its commitment to innovation and leadership in drug testing and monitoring. Through continuous advancements in laboratory medicine, Roche is shaping the future of drug testing and diagnostics.
Biography
With a career spanning over two decades in the IVD industry, Ya Yuan Lin is the International Product Manager for Mass Spectrometry at Roche Diagnostics. Her enthusiasm for introducing groundbreaking technologies to diagnostic laboratories across the globe is palpable, particularly in her close work with R&D to develop innovative solutions for toxicology. Since joining Roche Diagnostics in 2004, Ya Yuan has cultivated a broad understanding of the business through roles in technical support, marketing, and business development, leading to her current focus on mass spectrometry since 2017.
Prof Pieter Vermeersch
University of Leuven
Pushing the Boundaries of Clinical Mass Spectrometry: The Future of Diagnostics with the Roche cobas Ⓡ i 601
Abstract
Prof. Vermeersch will present findings from global multicenter evaluations on the cobas Ⓡ i 601 analyzer, a fully automated mass spectrometry system designed to improve workflow efficiency and reduce turn-around-time for LC-MS/MS analyses. The study assessed analytical performance, reliability, and practicality across different sets of analytes, including steroids, vitamins, immunosuppressants, antiepileptics, and antibiotics. Results demonstrated high throughput, precision, and strong agreement with current methods. Faster TAT for beta-lactams, voriconazole, and antiepileptics may enhance TDM and improve patient care, especially in critical care and emergency settings.
Biography
Pieter Vermeersch is a Professor of Medicine and Clinical Pathologist at the University Hospitals Leuven, Belgium, where he heads the special chemistry and mass spectrometry laboratory. His expertise spans therapeutic drug monitoring, toxicology, metabolic disorders and endocrinology, with a focus on cardiovascular and renal disease. Professor Vermeersch is dedicated to enhancing patient outcomes through the development of advanced mass spectrometry assays and improved test utilization. He also actively contributes to the field as the chairman of the EFLM Working Group Postanalytical Phase and a member of the EFLM Working Group Preanalytical Phase.
